Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies

Sponsor
Fred Hutchinson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05831540
Collaborator
(none)
114
1
3
10.6
10.8

Study Details

Study Description

Brief Summary

This clinical trial develops and tests how well a clinical decision support (CDS) tool works to increase human papillomavirus (HPV) vaccination of children between the age of 9-17 (adolescents) in pharmacies. HPV vaccination rate in eligible adolescents remains low even though over 90% of the cancers in adults caused by HPV can be prevented by the HPV vaccine. The National Vaccine Advisory Committee recommends HPV vaccinations to be given in pharmacies to increase access to vaccines, but pharmacy processes and lack of awareness of the service among parents impact the use of local pharmacies for HPV vaccinations. Using a focus group may be an effective method to develop a CDS tool and create a process that may be more convenient for parents to get their adolescent's vaccine at their local pharmacy. A CDS tool may make it easier to obtain HPV vaccines, and as a result increase the adolescent HPV vaccination rate and reduce the incidence of cancer caused by HPV.

Condition or Disease Intervention/Treatment Phase
  • Other: Discussion
  • Other: Educational Activity
  • Behavioral: Healthcare Activity
  • Other: Survey Administration
N/A

Detailed Description

OUTLINE: Participants are assigned to 1 of 3 groups.

Group I: Staff participate in facilitated planning discussions to develop CDS tools on study. (Aim I)

Group II: Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study. (Aim II)

Group III: Parents complete survey post-intervention on study. (Aim II)

Study Design

Study Type:
Interventional
Anticipated Enrollment :
114 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Clinical Decision Support Tools to Increase HPV Vaccination in Pharmacies
Anticipated Study Start Date :
May 14, 2023
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group I (staff focus group)

Staff participate in facilitated planning discussions to develop CDS tools on study.

Other: Discussion
Participate in focus group
Other Names:
  • Discuss
  • Other: Survey Administration
    Complete survey

    Experimental: Group II (staff CDS tool utilization)

    Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study.

    Other: Educational Activity
    Undergo training to use CDS tool

    Behavioral: Healthcare Activity
    Utilize CDS tool
    Other Names:
  • Health Care Activity
  • Healthcare
  • Other: Survey Administration
    Complete survey

    Experimental: Group III (parent survey)

    Parents complete survey post-intervention on study.

    Other: Survey Administration
    Complete survey

    Outcome Measures

    Primary Outcome Measures

    1. Development/refinement of the CDS tools to support and guide any adaptations to the pharmacy staff's vaccination workflow to improve vaccine delivery. (Aim 1) [Up to 6 months]

      The research team will analyze the collected qualitative data using framework-guided rapid analyses described by Gale et al. The qualitative data will be used to direct and document the development and refinement process for the CDS tools to support HPV vaccination and to guide any adaptations to the pharmacy staff's vaccination workflow to improve their delivery of HPV vaccine. Adaptations made to a pharmacy's vaccination workflow will be methodically documented using Stirman's Taxonomy of Adaptation Characteristics.

    2. Acceptability of CDS tools: Pharmacy staff (Aim II) [Post-implementation of CDS tools survey (at Months 11-12)]

      Will use validated survey measure to assess pharmacy staff's report of the acceptability of the CDS tools to support HPV Vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    3. Change in Acceptability of pharmacy-based HPV vaccination: Pharmacy staff (Aim II) [Pre-implementation of CDS Tools survey (at Months 4-5) and post- test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure acceptability of pharmacy-based HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    4. Acceptability of pharmacy-based HPV vaccination: Parents (Aim II) [Post-vaccination experience survey (at Months 8-12)]

      The survey will ask parents to respond to statements designed to measure acceptability of their vaccine experience at the pharmacy. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    5. Appropriateness of CDS tools: Pharmacy staff (Aim II) [Post-test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure appropriateness of the CDS tools to support HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    6. Appropriateness of pharmacy-based HPV vaccination: Pharmacy staff (Aim II) [Pre-test implementation survey (at Months 4-5) and post- test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure appropriateness of pharmacy-based HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    7. Appropriateness of pharmacy-based HPV vaccination: Parents (Aim II) [Post-vaccination experience survey (at Months 8-12)]

      The survey will ask parents to respond to statements designed to measure appropriateness of their vaccine experience at the pharmacy. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    8. Feasibility of CDS tools: Pharmacy staff (Aim II) [Post-test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure feasibility of the CDS tools to support HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    9. Feasibility of pharmacy-based HPV vaccination: Pharmacy staff (Aim II) [Pre-test implementation survey (at Months 4-5) and post- test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure feasibility of pharmacy-based HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    10. Feasibility of pharmacy-based HPV vaccination: Parents (Aim II) [Post-vaccination experience survey (at Months 8-12)]

      The survey will ask parents to respond to statements designed to measure feasibility of their vaccine experience at the pharmacy. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    11. Usability of CDS tools: Pharmacy staff (Aim II) [Post-test implementation survey (at Months 11-12)]

      The survey will ask pharmacy staff to respond to statements designed to measure usability of the CDS tools to support HPV vaccination. Survey responses will include 5-point scales: = Not at all confident = Not very confident = Neither (neutral) = Moderately confident = Completely confident And = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree

    12. Parents' experience Survey (Aim II) [Post-implementation of CDS tools up to 12 months]

      This is a 30-question survey asking about experience with getting child vaccinated at participating pharmacy. Survey responses will include a 5-point scales: = Strongly disagree = Somewhat disagree = Neither agree nor disagree = Somewhat agree = Strongly agree And Completely dissatisfied Somewhat dissatisfied Neither satisfied nor dissatisfied Somewhat satisfied Completely satisfied

    13. HPV vaccination rate per pharmacist at each pharmacy (Aim II) [12 months prior to CDS tool implementation (baseline) up to 5 months post-implementation]

      Outcomes of implementation analyzed using nonparametric tests appropriate for small sample statistics, like Wilcoxon sign-rank test.

    Secondary Outcome Measures

    1. Rate of other adolescent vaccinations per pharmacist at each pharmacy (Aim II) [12 months prior to CDS tool implementation (baseline) up to 5 months post-implementation]

      Outcomes of implementation analyzed using nonparametric tests appropriate for small sample statistics, like Wilcoxon sign-rank test.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • AIM I: >= 18 years

    • AIM I: Pharmacy staff: Employed at the partnering community pharmacies in Washington state

    • AIM I: Scientific Technologies Corportation (STC)Health staff: Employed at STCHealth

    • AIM I: PioneerRx staff: Employed at PioneerRx

    • AIM II: >= 18 years

    • AIM II: Parents: English speaking parent or guardian of at least one child, ages 9-17, living in Washington state and obtained an HPV vaccination for their child at a participating pharmacy and have access to a telephone or computer with internet access.

    • AIM II: Pharmacy staff: Employed at community pharmacies recruited into the study located in Washington state

    Exclusion Criteria:
    • Pharmacy staff: Floaters/per diem. Those who object to having the focus group discussions audio recorded. Those who object to participating in implementation evaluation surveys

    • STCHealth staff: Those who object to having the focus group discussions audio recorded

    • PioneerRx staff: Those who object to having the focus group discussions audio recorded

    • Parents: Those who decline to provide feedback on their experiences with getting their children vaccinated at the pharmacy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fred Hutch/University of Washington Cancer Consortium Seattle Washington United States 98109

    Sponsors and Collaborators

    • Fred Hutchinson Cancer Center

    Investigators

    • Principal Investigator: Parth Shah, Fred Hutch/University of Washington Cancer Consortium

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fred Hutchinson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT05831540
    Other Study ID Numbers:
    • RG1122655
    • NCI-2023-01989
    • 11086
    First Posted:
    Apr 26, 2023
    Last Update Posted:
    Apr 28, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Apr 28, 2023